A Multi-national Trial Evaluating Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Patients With Haemophilia A

Trial Profile

A Multi-national Trial Evaluating Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Patients With Haemophilia A

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Apr 2017

At a glance

  • Drugs Turoctocog alfa pegol (Primary)
  • Indications Haemophilia A
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms PATHFINDER 2
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 01 Dec 2016 Primary endpoint (the incidence rate of FVIII-inhibitors greater than or equal to 0.6 BU (Bethesda Unit)) has been met, according to results of pivotal analysis published in the Thrombosis and Haemostasis journal.
    • 01 Dec 2016 Primary endpoint (annualised bleeding rate in the prophylaxis arm) has been met, according to results of pivotal analysis published in the Thrombosis and Haemostasis journal.
    • 01 Dec 2016 Results of pivotal analysis, published in the Thrombosis and Haemostasis journal.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top